HCMV US11 based therapeutics that can be used to target and reduce the activity of the FcRn protein are provided. Methods of treating auto-immune mediated and albumin-mediated diseases in a subject are provided that comprise administration of HCMV US11 protein, polypeptide fragments, or variants thereof, as well as methods for preventing, or treating, infections of HCMV through administration of a US11 inhibitor. US11 protein containing vaccine compositions are also provided for stimulation of an anti-US11 immune response for protection against HCMV infection.

The present disclosure is drawn to HCMV US11 based therapeutics that can be used to target and reduce the activity of the FcRn protein. The disclosure provides a method of treating auto-immune mediated and albumin-mediated diseases in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising HCMV US11 (herein after referred to as “US11”) polypeptide, polypeptide fragments, or variants thereof. The disclosure also provides methods for preventing, or treating, infections of HCMV through administration of a US11 inhibitor. US11 containing vaccine compositions are also provided for stimulation of an anti-US11 immune response for protection against HCMV infection.

Provided herein, inter alia, are compositions and methods for treating or preventing viral infections. The methods and compositions may modulate entry of a virus into a cell, viral fusion to a cell, or cell to cell spread of the virus by targeting one or more viral proteins or ligands thereof. The methods and compositions provided herein including embodiments thereof are contemplated to be especially effective for treating or preventing cytomegalovirus infections.

The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.

Disclosed herein are compositions and uses thereof for detecting HIV latency reversal, isolating cells with HIV latency reversal, treating HIV infection, and/or reversing latency in HIV infected CD4+ T cells. In some aspects, disclosed herein is a composition and uses thereof for treating HIV infection, wherein the composition comprises one or more mature monocyte-derived dendritic cells (MDGs) having an HIV peptide bound to a Class I major histocompatibility complex (MHC) molecule and a herpesvirus peptide bound to one or more Class II MHC molecules.

The present disclosure provides T-cell modulatory multimeric polypeptides (T-Cell-MMPs) comprising an immunomodulatory polypeptide (MOD) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (Co-MOD) and a location for covalently attaching a molecule that can serve as an epitope, such as an epitope peptide. Once the epitope molecule is attached the resulting T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in an epitope selective/specific manner, and accordingly, for modulating an immune response in an individual.

The present disclosure is drawn to HCMV US11 based therapeutics that can be used to target and reduce the activity of the FcRn protein. The disclosure provides a method of treating auto-immune mediated and albumin-mediated diseases in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising HCMV US11 (herein after referred to as US11) polypeptide, polypeptide fragments, or variants thereof. The disclosure also provides methods for preventing, or treating, infections of HCMV through administration of a US11 inhibitor. US11 containing vaccine compositions are also provided for stimulation of an anti-US11 immune response for protection against HCMV infection.

The present disclosure describes a nucleic acid delivery construct comprising at least one sense or antisense RNA subdomain of the human cytomegalovirus 2.7 RNA, wherein each subdomain is capable of localization within the mitochondria, for transport into mitochondria. Disclosed herein are also methods of enhancing mitochondrial gene function, or suppressing defective mitochondrial gene function, or both, as well as methods of treating a mitochondrial disorder.

Herein is reported a disulfide-linked multivalent multi-function protein, characterized in that it comprises two or more antigen presenting domains, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a 2-microglobulin, and (ii) the extracellular domains 1, 2, and 3 of a class I MHC molecule with a relative frequency of less than 1%, or (i) a T-cell response eliciting peptide, (ii) a 2-microglobulin, and (iii) the extracellular domains 1, 2, and 3 of a class I MHC molecule with a relative frequency of 1% or more, wherein the antigen binding site binds to a cancer cell surface antigen or a virus-infected cell surface antigen and wherein the antigen presenting domain has at least two non-naturally occurring cysteine residues which form an intrachain/interdomain disulfide bond.

Herein is reported a multi-function protein, characterized in that it comprises exactly one antigen presenting domain, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a 2-microglobulin, and (ii) the extracellular domains 1, 2, and 3 of a class I MHC molecule with a relative frequency of less than 1%, or (i) a T-cell response eliciting peptide, (ii) a 2-microglobulin, and (iii) the extracellular domains 1, 2, and 3 of a class I MHC molecule with a relative frequency of 1% or more, wherein the antigen binding site binds to a cancer cell surface antigen.